Literature DB >> 12378376

Trends in hypertension management in Type I diabetes across Europe, 1989/1990 - 1997/1999.

S S Soedamah-Muthu1, H M Colhoun, H Abrahamian, N N Chan, R Mangili, G P Reboldi, J H Fuller.   

Abstract

AIMS/HYPOTHESIS: Our aim was to examine the change in the management of hypertension in patients with Type I (insulin-dependent) diabetes mellitus in Europe, between 1989-1990 and 1997-1999.
METHODS: Seven-year changes in hypertension treatment and control (defined as blood pressure <130/85 mmHg) were examined in a large sample of Type I diabetic patients recruited from 26 centres involved in the EURODIAB Prospective Complications Study. Hypertension was defined as a systolic and/or diastolic blood pressure greater than 140 and/or 90 mmHg respectively, and/or use of blood pressure lowering drugs.
RESULTS: Of 1866 Type I diabetic patients, 412 had hypertension at baseline and 631 at follow-up. A greater proportion of hypertensive patients were treated at follow-up (69% vs 40%, p<0.0001), which persisted after adjustment for age or centre. Of those who were treated, a modest increase in the proportion of those controlled for hypertension was found (41% vs 32%, p=0.048), which disappeared after adjustment for age. Among hypertensive patients with albuminuria, the proportions treated also increased, from 35% to 76% ( p<0.0001) in microalbuminuric and 64% to 95% ( p<0.0001) in macroalbuminuric patients. Control of hypertension in albuminuric patients did not change significantly and was below 50%. The use of more than one anti-hypertensive drug increased over a 7-year period, from 19% to 33% ( p<0.0001), and a marked increase was shown in the proportion of those taking an ACE inhibitor (from 57% to 82%, p<0.0001). CONCLUSION/
INTERPRETATION: The management of hypertension in Type I diabetic patients across Europe has improved over a 7-year follow-up period. Optimal levels of blood pressure treatment and optimal levels of control have not yet been achieved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378376     DOI: 10.1007/s00125-002-0914-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  60 in total

1.  Superior physicians and the treatment of hypertension.

Authors:  Jerome D Cohen
Journal:  Arch Intern Med       Date:  2002-02-25

2.  Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study.

Authors:  F Collado-Mesa; H M Colhoun; L K Stevens; J Boavida; J B Ferriss; B Karamanos; P Kempler; G Michel; G Roglic; J H Fuller
Journal:  Diabet Med       Date:  1999-01       Impact factor: 4.359

Review 3.  Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence.

Authors:  N M Kaplan
Journal:  Ann Intern Med       Date:  2001-12-18       Impact factor: 25.391

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Prevalence, awareness, treatment, and control of hypertension in Greece: the Didima study.

Authors:  G S Stergiou; G C Thomopoulou; I I Skeva; T D Mountokalakis
Journal:  Am J Hypertens       Date:  1999-10       Impact factor: 2.689

6.  Trends in hypertension prevalence and management in Southwestern France, 1985-1996.

Authors:  P Marques-Vidal; J B Ruidavets; J P Cambou; J Ferrières
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

7.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

8.  Levels and trends in blood pressure and prevalence and treatment of hypertension in The Netherlands, 1987-1991.

Authors:  E M van Leer; J C Seidell; D Kromhout
Journal:  Am J Prev Med       Date:  1994 Jul-Aug       Impact factor: 5.043

9.  Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.

Authors: 
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

10.  Detection and control of hypertension in the population: the United States experience.

Authors:  P J Mulrow
Journal:  Am J Hypertens       Date:  1998-06       Impact factor: 2.689

View more
  4 in total

Review 1.  Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies.

Authors:  Donna L McLean; Scot H Simpson; Finlay A McAlister; Ross T Tsuyuki
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

2.  Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.

Authors:  J W M Nin; I Ferreira; C G Schalkwijk; M H Prins; N Chaturvedi; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2009-01-30       Impact factor: 10.122

3.  Prevalence, awareness, and treatment of hypertension in patients with type 1 diabetes: a nationwide multicenter study in Brazil.

Authors:  Marilia B Gomes; Lucianne Righeti Monteiro Tannus; Alessandra Saldanha de Mattos Matheus; Roberta Arnoldi Cobas; Catia C Sousa Palma; Aline Tiemi Kano Silva; Carlos Antonio Negrato; Sergio Atala Dib; Melanie Rodacki; João Soares Felício; Luis Henrique Canani
Journal:  Int J Hypertens       Date:  2013-03-04       Impact factor: 2.420

4.  Trends in hypertension prevalence, awareness, treatment and control in an adult type 2 diabetes Spanish population between 2003 and 2009.

Authors:  Carmen de Burgos-Lunar; Rodrigo Jiménez-García; Miguel A Salinero-Fort; Paloma Gómez-Campelo; Angel Gil; Juan C Abánades-Herranz; Juan Cárdenas-Valladolid; Isabel del Cura-González
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.